Indian drugmakers anticipate a mixed third quarter. Domestic sales and new specialty drugs will drive growth. US generics will see new product boosts. Contract services and APIs are set for moderate gains. Sun Pharma and Lupin are poised for leadership. Cipla and Dr Reddy’s face softer US sales. Divi’s Laboratories expects strong custom synthesis growth.
Hindustan Copper shares gain 3% as company plans Rs 7,000 crore capital investment in next 5 years
Hindustan Copper shares rose after the company announced a Rs 7,000 crore investment over the next 5-6 years and signed MoUs with major PSUs to